Verdens Gang (VG), Norway’s largest newspaper, recently featured an article on the SPIOMET4HEALTH Polycystic Ovary Syndrome (PCOS) study. The article highlighted the involvement of 19-year-old Emma, who is actively participating in the groundbreaking SPIOMET4HEALTH study on PCOS. Leading the study in Norway is Professor Eszter Vanky (NTNU), a renowned gynecologist and the local principal investigator at St. Olav’s Hospital in Trondheim.
PCOS symptoms and potential treatment
Emma, like many others, experienced symptoms such as weight gain, acne, irregular menstruation, and emotional turmoil. However, she lacked proper information and support. Frustrated, she turned to social media for answers, only to encounter a flood of conflicting advice and remedies. That’s when Emma’s path intersected with Professor Eszter Vanky.
PCOS affects approximately 15 percent of all Norwegian women. Recognizing the pressing need for effective solutions, the EU-funded SPIOMET4HEALTH study was initiated. This groundbreaking study involves Emma and 39 other young Norwegian women, aged 12 to 24, who are receiving a tailored combination of three medications specifically designed for PCOS treatment. The study aims to understand how these medications work together and provide potential solutions for younger women with the condition. Emma’s involvement includes medication, regular tests, personalized dietary and lifestyle guidance, and a comprehensive study duration of twelve months. In the article, she highlights that she remains hopeful and appreciates being part of a network dedicated to finding answers.
Read the Full Article (in Norwegian): Ny studie om PCOS gir håp: – Man blir jo desperat til slutt – VG
How to participate in the Spiomet4health clinical trial
SPIOMET4HEALTH is a project that aims to provide a novel treatment for adolescent girls and young women with Polycystic Ovary Syndrome (PCOS). PCOS negatively affects the health and quality of life of approximately 110 million women who suffer from this syndrome.
If you are between the ages of 12 and 24 and are interested in participating in the clinical trial, you can click here to learn more. Participation is possible in Spain, Norway, Denmark, Italy, Austria and Turkey.